Dissociation of antitremorine activity and clinical antiparkinsonian effect. A clinical trial of AGN 511 in postencephalitic parkinsonism.
D000818:Animals; D001463:Barbiturates / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D051379:Mice; D010276:Parasympatholytics / Q000627:therapeutic use; D010301:Parkinson Disease, Postencephalitic / Q000188:drug therapy*; D010880:Piperidines / Q000627:therapeutic use*; D014202:Tremor / Q000139:chemically induced / Q000188:drug therapy; D014203:Tremorine / Q000037:antagonists & inhibitors
D001463:Barbiturates; D010276:Parasympatholytics; D010880:Piperidines; D014203:Tremorine